MBRX
Moleculin Biotech·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Consensus Rating "Strong Buy"
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MBRX
Moleculin Biotech, Inc.
A clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses
5300 Memorial Drive, Suite 950, Houston, Texas 77007
--
Moleculin Biotech, Inc., a clinical drug development company founded in July 2015 in Delaware, focuses on the development of anti-cancer drugs, mainly in cooperation with the M.D. Anderson Cancer Center of the University of Texas. The company's main drug is the lipid anamycin, which is used to treat relapsed or acute leukemia. In addition to two other drugs under development, one is WP1066, which mainly controls key transcriptional regulatory factors involved in cancer; the other is WP1122, which mainly affects the metabolic process of cancer cells through molecular targets.
Company Financials
EPS
MBRX has released its 2025 Q2 earnings. EPS was reported at -0.49, versus the expected -1.25, beating expectations. The chart below visualizes how MBRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
